[ad_1]
Nader Pourhbadan, CEO of CytoDyn Inc. (OTCQB: CYDY), tells Proactive Investors that biotech recently held a shareholder meeting on May 22, during which company executives discussed the potential its license agreement and the progress of its ongoing clinical trials.
Pourhbadan announced today that he will be going to South Korea to meet the company producing the flagship CytoDyn drug, leromlimab, Samsung BioLogics Co.
Source link
